Navigation Links
Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/10/2013

ed by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended March 31, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

 

 

 INOVIO PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS March 31, 2013December 31,
2012(Unaudited)ASSETSCurrent assets:Cash and cash equivalents

$

20,086,799$

5,646,021Short-term investments

7,978,3458,034,001Accounts receivable

1,029,158830,433Accounts receivable from affiliated entity

43,53736,234Prepaid expenses and other current assets

283,044471,328Prepaid expenses and other current assets from affiliate
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
2. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
5. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
6. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... (PRWEB) May 27, 2015 Empowering ... to combat disease, Cubresa Inc. today announced its ... MR Compatible in-bore PET Scanner uses silicon photomultiplier ... single-purpose preclinical MRI machines from manufacturers like Bruker ... headquartered in Winnipeg, Canada. “This enables simultaneous PET ...
(Date:5/27/2015)... 27, 2015  Two years after its founding by ... citizen scientists, Oakland -based Counter Culture ... its mission to democratize science through a full-fledged community ... Photo - ... Based out of the new Omni ...
(Date:5/27/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... status of the Company,s Series A and Series ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO At March ... of Series A Preferred Stock and Series A-1 ...
(Date:5/26/2015)... 26, 2015 The University of ... Max Planck Society establishing the Max Planck-University ... center will link two of the world's foremost research ... only the third Max Planck Centre in North America. ... for optics and photonics, was with university and ...
Breaking Biology Technology:Cubresa Launches Simultaneous PET/MRI Technology 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3
... Dr. John McPherson, Platform Leader, Cancer Genomics and ... the Ontario Institute for Cancer Research (OICR) led a ... of the NEBNext(TM) DNA Sample Prep Reagents for use ... of the evaluation, "We are constantly striving for the ...
... The U.S. Environmental Protection Agency today outlined a ... nanomaterials may harm human health and the environment. ... and 100 nanometers. A nanometer is approximately 1/100,000 ... are currently used in hundreds of consumer products, ...
... ... , ... 2009 -- Counterfeit and adulterated food and drugs and advances in measurement science used to ... U.S. Pharmacopeial (USP) Convention. Held in Toronto, Canada, more than 300 people from 26 countries ...
Cached Biology Technology:Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing 2EPA announces research strategy to study nanomaterials 2Global Public Health the Focus of Scientific Conference 2Global Public Health the Focus of Scientific Conference 3
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
(Date:5/19/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... ball out of a scrum herpes virus can cause a ... have studied the spread of the disease among sumo wrestlers in ... could be even more pathogenic, according to an article published in ... "Scrumpox", or herpes gladiatorum , is a skin ...
... essential nutrient involved in vision, growth, cellular differentiation, and ... is chaperoned through the body on carrier proteins. ... funded by USDA and NIH, discovered that not only ... retinol-binding protein (RBP), elevated in obese individuals compared to ...
... William Metcalf and his collaborators have developed a way ... of malaria less expensive. Metcalf set ... group known as phosphonates, is made in nature by ... some phosphonates have antibiotic properties. Recently, Metcalf and his ...
Cached Biology News:Deadly rugby virus spreads in sumo wrestlers 2Don't forget the vitamin A when working with its carrier protein 2New way to make malaria medicine also first step in finding new antibiotics 2New way to make malaria medicine also first step in finding new antibiotics 3New way to make malaria medicine also first step in finding new antibiotics 4
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
...
... The SelectFX Alexa Fluor 488 Cytochrome ... reagents you need to detect cytochrome c ... anti-cytochrome c primary antibody and an ... Fluor 488 dye exhibits bright green fluorescence ...
For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
Biology Products: